Black Diamond Therapeutics, Inc. (BDTX) Hits Fresh High: Is There Still Room to Run?

Company Performance - Black Diamond (BDTX) has seen a strong performance, with shares up 22.9% over the past month and a 115.9% increase since the start of the year, compared to 4.6% for the Zacks Medical sector and 15.9% for the Zacks Medical - Biomedical and Genetics industry [1] - The stock reached a new 52-week high of $4.65 in the previous session [1] Earnings and Valuation - Black Diamond has a record of positive earnings surprises, beating the Zacks Consensus Estimate in each of the last four quarters, with the latest EPS reported at -$0.15 against a consensus estimate of -$0.22 [2] - For the current fiscal year, Black Diamond is expected to post earnings of $0.46 per share on revenues of $70 million [2] - The stock currently trades at 10X current fiscal year EPS estimates, below the peer industry average of 18.8X [5] Zacks Rank and Style Scores - Black Diamond holds a Zacks Rank of 2 (Buy) due to favorable earnings estimate revisions from analysts [6] - The company has a Value Score of B, and both Growth and Momentum Scores of A, resulting in a combined VGM Score of A [5][7] Industry Comparison - The Medical - Biomedical and Genetics industry is in the top 34% of all industries, indicating favorable conditions for companies like Black Diamond and its peers [10] - Emergent Biosolutions Inc. (EBS), a peer in the industry, has a Zacks Rank of 1 (Strong Buy) and has shown strong earnings performance, beating consensus estimates by 983.33% [8][9]